Teva, Sanofi say bowel disease drug met primary targets (Dec 17)
Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping it will become a blockbuster drug - or one that generates annual sales of at least $1 billion.
Teva Stock Soars on Early Bowel Disease Drug Data
Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical remission, compared with 20.5% who received a placebo.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment of Ulcerative Colitis (UC) and Crohn's disease (CD),
TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals?
Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn’s disease,
Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
US affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative colitis and Crohn's disease are the most common types of inflammatory bowel disease.
Teva Stock Surges To 6-Year High On Inflammatory Bowel Disease Drug Trial Data: Retail Chatter Erupts
Shares of Teva Pharmaceutical Industries surged more than 23% on Tuesday afternoon, reaching levels not seen since December 2018, driven by positive data from a trial of a drug candidate aimed at treating inflammatory bowel disease (IBD).
FierceBiotech1d
Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...
A Game Plan for Your Moderate-to-Severe Ulcerative Colitis
The symptoms of UC are unpredictable. On a given day it can cause an urge to use the bathroom repeatedly, or blood in your ...
Medindia4d
Beta Ionone: A New Hope for Ulcerative Colitis Patients
Discover how β-ionone offers relief from ulcerative colitis by enhancing gut health, reducing inflammation, and restoring ...
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative ...
ktvh8h
Non-profit VEO Guardians helps a Helena boy
Gabe, Volpe's son was diagnosed with pan- ulcerative colitis and his treatment path was filled with complications leaving him ...
The Lancet1d
Guselkumab in the IL-23 inhibition landscape for ulcerative colitis
The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...
Medical Xpress on MSN2d
Electrical stimulation of ears shows promise for treating ulcerative colitis
A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a ...